We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Management of bone metastases in refractory prostate cancer - role of denosumab.

Mechanism of action of denosumab.
Note: Copyright© 2012. Nature Publishing Group. Reproduced with permission from Lewiecki EM, Bilezikian JP. Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin Pharmacol Ther. 2012;91(1):123–133.43
Abbreviations: RANKL, receptor activator of nuclear factor-κB legends; RANK, receptor activator of nuclear factor-κB.

Channing J Paller, et al. Clin Interv Aging. 2012;7:363-372.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk